John Devane

Dr. Devane currently serves as a scientific advisor and board member to Saol Therapeutics. He is also a board member of Sebela Pharmaceuticals and is an advisor to Avego Healthcare Capital. Previously, Dr. Devane was Chief Scientific Officer (CSO) with Horizon Pharma Ireland Ltd. and (2012-2014) served as CSO at Vidara Therapeutics Research Ltd. In the past, Dr. Devane was part of the founding team of AGI Therapeutics plc. and served as its CEO from 2004-2012. Additionally, Dr. Devane founded and led Athpharma Ltd. as CEO from 2002-2005. Dr. Devane worked for Elan Corporation from 1981 to 2001 and held various senior leadership positions, including Executive Vice President R&D (1993-2001) and Senior Vice President Clinical & Regulatory, where he led key clinical trial programs in the USA and negotiated NDA approvals directly with FDA. During the period 1990 to 2001, Dr. Devane and his team were responsible for 6 NDA and 3 ANDA approvals. Dr. Devane has had a long career designing and successfully delivering major product development programs spanning the full range of drug development. He has deep knowledge in pharmacology, drug delivery, clinical development, regulatory affairs, and intellectual property. Dr. Devane is the inventor/co-inventor on many granted and pending patent applications and has also been widely published in the scientific/medical literature. His graduate and post-graduate scientific training were conducted at University College in Dublin, Ireland. He holds a diploma in Accounting & Finance (ACCA and is a certificate/diploma holder from the Institute of Directors (UK).